Bydureon (Amylin and Alkermes), a once-weekly formulation of exenatide, has been made available for the treatment of type 2 diabetes. Bydureon and Byetta (Amylin and Lilly) both contain the same active ingredient, exenatide, and therefore should not be used together.
Bydureon is an injectable suspension formulation that is administered subcutaneously. It will be supplied in cartons of four single-dose trays that include one vial containing 2mg exenatide, one prefilled syringe containing diluent, one vial connector, and two custom needles specific to this delivery system.
For information, call (877) 700-7365 or visit www.bydureon.com.